Document is current
Any future updates will be listed below
-
Authors
Powers, John H. III
Ballinger, Rachel
De Palma, Andrea
de la Cruz, Marie
Howard, Kellee
-
Funding
Funding for this research was provided by:
Spine BioPharma, LLC
- License Information
-
More Information
Article History
Received: 13 February 2024
Accepted: 30 October 2025
First Online: 8 January 2026
Declarations
:
: The study obtained ethics approval from Salus IRB (Independent Review Board) in Austin, Texas. All IRB approvals are available from the corresponding author on reasonable request. All participants gave informed consent prior to taking part in the study.
: Participants consented to de-identified data being used in any publication.
: RB, ADP, MDLC and KH received study funding from Spine BioPharma, LLC to conduct this study. JP has served as consultant for: Aceragen, Adaptive Phage, Arrevus, Eicos, Evofem, Eyecheck, Gilead, GlaxoSmithKline, OPKO, Otsuka, Resolve, Romark, Spine BioPharma, UTIlity and Vir.
